Lipocine Inc. Files 8-K
Ticker: LPCN · Form: 8-K · Filed: Oct 10, 2024 · CIK: 1535955
| Field | Detail |
|---|---|
| Company | Lipocine Inc. (LPCN) |
| Form Type | 8-K |
| Filed Date | Oct 10, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k
TL;DR
Lipocine filed an 8-K, no major news yet.
AI Summary
Lipocine Inc. filed an 8-K on October 10, 2024, reporting other events and financial statements. The filing does not contain specific details about new events, material agreements, or financial results, but rather serves as a procedural update.
Why It Matters
This 8-K filing indicates Lipocine Inc. is fulfilling its reporting obligations with the SEC, though it doesn't disclose new material information at this time.
Risk Assessment
Risk Level: low — The filing is a routine procedural update and does not contain information that would immediately impact the company's risk profile.
Key Players & Entities
- Lipocine Inc. (company) — Registrant
- October 10, 2024 (date) — Date of Report
- 001-36357 (other) — Commission File Number
- Delaware (other) — State of Incorporation
- 99-0370688 (other) — IRS Employer Identification Number
- 675 Arapeen Drive, Suite 202 (other) — Principal Executive Offices Address
- Salt Lake City, Utah 84108 (other) — Principal Executive Offices Location
- (801) 994-7383 (other) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing by Lipocine Inc.?
The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of October 10, 2024.
When was this 8-K filing submitted by Lipocine Inc.?
This 8-K filing was submitted on October 10, 2024.
What is Lipocine Inc.'s Commission File Number?
Lipocine Inc.'s Commission File Number is 001-36357.
In which state was Lipocine Inc. incorporated?
Lipocine Inc. was incorporated in Delaware.
What is the address of Lipocine Inc.'s principal executive offices?
The address of Lipocine Inc.'s principal executive offices is 675 Arapeen Drive, Suite 202, Salt Lake City, Utah 84108.
Filing Stats: 430 words · 2 min read · ~1 pages · Grade level 11.5 · Accepted 2024-10-10 06:04:19
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share LPCN The NASDAQ Stock Mar
Filing Documents
- form8-k.htm (8-K) — 43KB
- ex99-1.htm (EX-99.1) — 28KB
- form8-k_001.jpg (GRAPHIC) — 6KB
- ex99-1_001.jpg (GRAPHIC) — 82KB
- 0001493152-24-040651.txt ( ) — 378KB
- lpcn-20241010.xsd (EX-101.SCH) — 3KB
- lpcn-20241010_lab.xml (EX-101.LAB) — 33KB
- lpcn-20241010_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LIPOCINE INC. Date: October 10, 2024 By: /s/ Mahesh V. Patel Mahesh V. Patel President and Chief Executive Officer